Anticancer activities and mechanisms of bisdioxopiperazine compounds probimane and MST-16

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 78-91

  Lu, Da Yong ^a   Lu, Ting Ren ^a  

^a SHANGHAI UNIVERSITY   (China)

Author keywords

Anti neoplastic drugs; Anticancer pharmacology; Antimetastatic drugs; Bisdioxopiperazine; Calmodulin; Cell cycle arrest; Cell movement; Drug metabolism; Fibrinogen; Lipoperoxidation; MST 16; Neoplasm metastasis; Probimane; Razoxane; Sialic acids

Indexed keywords

1,2 BIS(3,5 DIOXOPIPERAZIN 1 YL)ETHANE; ALPHA ANORDRIN; ANTINEOPLASTIC AGENT; BIMOLANE; CALMODULIN; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CORTISONE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FIBRINOGEN; FLUOROURACIL; HARRINGTONINE; HOMOHARRINGTONINE; HYDROXYCAMPTOTHECIN; LYCOBETAINE; MITOMYCIN C; OXALYSINE; PROBIMANE; RAZOXANE; SIALIC ACID; SOBUZOXANE; THIOTEPA; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DIVISION; CELL MOTION; CHROMOSOME SEGREGATION; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TISSUE LEVEL; ERYTHROCYTE; HUMAN; IMMUNE STATUS; IN VITRO STUDY; IN VIVO CULTURE; LETHALITY; LEWIS CARCINOMA; LIPID PEROXIDATION; LUNG ADENOCARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; MITOSIS INHIBITION; ROSETTE FORMATION; SIGNAL TRANSDUCTION; TUMOR NECROSIS;

EID: 77950853791     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009010078     Document Type: Article

References (62)

1. Herman, E.H.; Witiak, D.T.; Hellmann, K.; Waradek, V.S. Properties of ICRF-159 and related Bis(dioxopiperazine) compounds. Advances in Pharmacology and Chemotherapy, Garattini S.; Goldin A.; Hawking, F.; Kopin, I.J.; Eds. New York: Academy Press 1982, Vol 19, pp. 249-290.
2. Hellmann, K.; Burrage K. Control of malignant metastases by ICRF-159. Nature, 1969, 224(5216), 273-275
3. Lu, D.Y.; Xu, Bin.; Ding, J. Anti-tumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo. BMC Pharmacol., 2004, 4, 32.
4. Lu, D.Y.; Huang, M.; Xu, C.H.; Yang, W.Y.; Hu, C.H.; Lin, L.P.; Tong, L.J.; Li, M.H.; Lu, W.; Zhang, X.W.; Ding, Jian. Antiproliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. BMC Pharmacol., 2005, 5, 11.
5. Lu, D.Y.; Huang, M.; Xu, C.H.; Zhu, H.; Xu, B.; Ding, J. Medicinal chemistry of probimane and MST-16: comparison of anticancer effects between bisdioxopiperazines. Med. Chem., 2006, 2(4), 369-375.
6. Ji, R.Y. Probimane. Drugs Future, 1988, 13(4), 418-419.
7. He, H.; Wang, M.Y.; Zhang, T.M. Cytokinetic effects of 1, 2-bis(4- isobutoxycarbonyloxymethyl- 3, 5-dioxopiperazin-1-yl) ethane( MST-16) on leukemia L1210 cells in mice. Acta. Pharmacol. Sin., 1988, 9(4), 369-373.
8. Narita, T.; Koide, Y.; Yaguchi, S.; Kimura, S.; Izumisawa, Y.; Takasa, M.; Inaba, M.; Tsukagoshi, S. Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2, 6-dioxopiperazine). Cancer Chemother. Pharmacol., 1991, 28(4), 235-240.
9. Okamoto, T.; Nishimura, Y.; Yamada, S.; Yamada, S.; Itoh, T.; Mori, A.; Saheki, K.; Okada, M.; Takatsuka, H.; Wada, H.; Tamura, A.; Fujimori, Y.; Kakishita, E. Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP- 16, for refractory or relapsed non-Hodgkin's lymphoma. Acta. Haematol., 2000, 104(2-3), 128-130.
10. Lu, D.Y.; Xu, B. Pharmacological study of antineoplastic agent probimane. Chin. J. Pharm., 1996, 27(6), 255-257.
11. Lu, D.Y.; Wu, F.G.; Cao, J.Y.; Gong, L.; Xu, B. Influence of pulmonary metastasis of three bisdioxopiperazines on Lewis lung carcinoma in vivo. Chin. Pharmacol. Bull., 2000, 16(5), 540-541.
12. Lu, D.Y.; Cao, J.Y; Yin, J.L.; Chen, E.H.; Xu, B. Protective effect of probimane on cell calmodulin and hemolysis. Chin. Pharmacol. Bull., 1995, 11(4), 338-340.
13. Lu, D.Y.; Chen, E.H.; Cao, J.Y.; Zhou, J.J.; Shen, Z.M.; Xu, B.; Horie, K. Comparison between probimane and razoxane on inhibiting calmodulin activity of rabbit erythrocyte membrane. Chin. J. Pharmacol.Toxicol., 2001, 15(1), 76-78.
14. ++-ATPase system of blood cells inhibited by α-anordrin and probimane. J. Shanghai Univ.(Engl.), 1998, 2(1), 81-83.
15. Lu, D.Y.; Chen, E.H.; Cao, J.Y.; Xu, B.; Ding, J. The antiproliferative effects of probimane and razoxane on tumor cells are concomitant with inhibition of hemolysis and calmodulin(CaM) action and a new CaM-ATPase acting model. Res. J. Biol. Sci., 2007, 2(2), 127-133.
16. Lu, D.Y.; Cao, J.Y.; Gong, L.; Chen, E.H.; Chen, W.Z.; Xu, B. Inhibition of probimane on lipoperoxidation of human red cells in vitro. J . Shanghai Univ(Engl.), 1998, 2(4), 326-327.
17. Lu, D.Y.; Chen, E.H.; Cao, J.Y.; Jin, W.; Tian, F.; Ding, J. The inhibition of probimane on lipid peroxidation of rabbit and human erythrocytes. J. Shanghai Univ.(Engl.), 2003, 7(3), 301-304.
18. Zhang, Y.; Zhang, T.M.; Liu, B.L.; Han, J.K.; Chen, W.C.; Xin, W.J. Scavenging of probimane on semiquinone free radical formation by doxorubicin in rat heart. Acta. Pharmacol. Sin., 1991, 12(1), 20-23.
19. Zhang, Y.; Zhang, T.M. Effect of probimane on lipid peroxidation caused by doxorubicin in rats. Chin . J. Pharmacol. Toxicol., 1992, 6(2), 118-120.
20. Zhang, Y.; Hua, H.Y.; Zhang, T.M. Inhibitory effect of dioxopiperazine compounds on malondialdehyde induced by doxorubicin in rat liver mitochondria in vitro. Acta. Pharmacol. Sin., 1993, 14(4), 340-343.
21. Lu, D.Y.; Chi, J.; Lin, L.P.; Huang, M.; Xu, B.; Ding, J. Effect of anticancer drugs on the binding of 125I-fibrinogen to two leukemia cell lines in vitro. J. Int. Med. Res., 2004, 32(4), 488-491.
22. Lu, D.Y.; Cao, J.Y.; Huang, Y.P.; Gong, L.; Chen, X.L.; Chen, E.H.; Xu, B. Comparison of some antineoplastic drugs on inhibiting thrombin catalyzing fibrinogen clotting in vitro. Chin. Med. J.,(Engl.), 1999, 112(11), 1052-1053.
23. Yue, XF.; Wu, F.G.; Xu, B. Effect of oxalysine on plasma fibrinogen content in tumor-bearing mice. Acta. Pharmacol Sin., 1982, 3(2), 124-128.
24. Lu, D.Y.; Liang, G.; Zhang, M.J.; Xu, B. Serum contents of sialic acids in mice bearing different tumors. Chin. Sci. Bull.(Engl.), 1994, 39(14), 1220-1223.
25. Lu, D.Y.; Xu, J.; Xu, B.; Zhou, A.M. Influence of several antineoplastic drugs on serum sialic acids of mice bearing tumors. Chin. Biochem. J., 1993, 9(5), 626-630
26. Lu, D.Y.; Cao, J.Y. Structural aberration of cellular sialic acids and their functions in cancer. J. Shanghai Univ.(Engl.), 2001, 5(2), 164-170.
27. Lu, D.Y.; Li, F.R.; Xu, B. Experimental research of mouse lymphocyte rosette formation. Chin. Pharmacol. Bull., 1993, 9(4), 310-311.
28. Lu, D.Y.; Zhang, S.Y.; Chen, R.T.; Zhang, X.; Xu, B. Studies on antitumor action and absorption, distribution and excretion of probimane. Chin. J. Pharm., 1989, 20(7), 327-330.
29. Lu, D.Y.; Xu, B.; Zhang, X.; Chen, R.T. Distribution of 14C labeled at dioxopiperazine or methyl morphorline group of probimane by whole body autoradiography. Acta. Pharmacol. Sin., 1993, 14(2), 171-173.
30. Braybrooke, J.P.; O'Byrne, K.J.; Propper, D.J.; Blann, A.; Saunders, M.; Dobbs, N.; Han, C.; Woodhull, J.; Mitchell, K.; Crew, J.; Smith, K.; Stephens, R.; Ganesan, T.; Talbot, D.C.; Harris, A.L. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin. Cancer Res., 2000, 6(12), 4697-4704.
31. Hellmann, K. Dynamics of tumor angiogenesis: effect of razoxaneinduced growth rate slowdown. Clin. Exp. Metastasis., 2003, 20(2), 95-102.
32. Taraboletti, G.; Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr. Opin. Pharmacol., 2001, 1(4), 378-384.
33. Lu, D.Y.; Huang, M.; Zhou, J.; Ding, J. Recent advances in antimetastatic drug development. Acta. Pharmacol. Sin., 2006, 27(Suppl), 66-67.
34. Lu, D.Y.; Huang, M.; Zhou, J.; Ding, J. Recent advances in antimetastatic drug developments. Henan. Med. Res., 2004, 13(3), 273-281.
35. Liotta, L.A.; Kohn, E.C. The microenvironment of the tumour-host interface. Nature, 2001, 411(6835), 375-379.
36. Poste, G.; Fidler, I.J. The pathogenesis of cancer metastasis. Nature, 1980, 283(5742), 139-146.
37. Fidler, I.J. Critical factors in the biology of human cancer metastasis: Twenty-eight GHA Clowes memorial award lecture. Cancer Res., 1990, 50(19), 6130-6138.
38. Fidler, I.J. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat. Rev. Cancer, 2003, 3(6), 453-458.
39. Lu, D.Y.; Cao, J.Y. Review of experimental pathologic studies on tumor metastases. Henan. Med. Res., 2000, 9(3), 282-285.
40. James, S.E.; Salsbury, A.J. Effect of(±)-1,2-bis(3,5- dioxopiperazin- 1-yl) propane non tumor blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma. Cancer Res., 1974, 34(4), 839-842.
41. Sava, G.; Bergamo, A. Drug control of solid tumour metastases: a critical view. Anticancer Res., 1999, 19(2A), 1117-1124.
42. Salsbury, A.J.; Burrage, K.; Hellmann, K. Histological analysis of the antimetastatic effect of(±)-1,2-bis(3,5-dioxopiperazin-1-yl) propane. Cancer Res., 1974, 34(4), 843-849.
43. Lipinski, B. Rationale for the treatment of cancer with sodium selenite. Med. Hypotheses, 2005, 64(3), 806-810.
44. Means, A.R.; VanBerkum, M.F.A.; Bagchi, I.; Lu, K.P.; Rasmussen, C.D. Regulatory functions of calmodulin. Pharmacol. Ther. Taylor Ed, Pergamon Press, UK, 1991, Vol 50, pp 255-270.
45. Krebs, J. Calmodulin-dependent protein kinase IX; regulation of function and expression. Biochim. Biophys. Acta, 1998, 1448(2), 183-189.
46. Hait, W.N. Targeting calmodulin for the development of novel cancer chemotherapeutic agents. Anticancer Drug Des., 1987, 2(2), 139-149.
47. Rodriguez-Mora, O.; LaHair, M.M.; Howe, C.J.; McCubrey, J.A.; Franklin, R.A. Calcium/ calmodulin-dependent protein kinases as potential targets in cancer therapy. Expert Opin. Ther. Targets, 2005, 9(4), 791-808.
48. Dvorak, H.F.; Senger, D.R.; Dvorak, A.M. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev., 1983, 2(1), 41-73.
49. Costantini, V.; Zacharski, L.R. The role of fibrin in tumor metastasis. Cancer Metastasis Rev., 1992, 11(3), 283-290.
50. Staton, C.A.; Brown, N.J.; Lewis, C.E. The role of fibrinogen and related fragments in tumour angiogenesis and metastasis. Expert Opin. Biol. Ther., 2003, 3(7), 1105-1120.
51. Dvorak, H.F. Tumor wounds that do not heal, similarities between tumor stroma generation and wound healing. N. Engl. J. Med., 1986, 315(26), 1650-1659.
52. Lu, D.Y.; Chen, X.L.; Cao, J.Y.; Li, Z.; Xue, H.W.; Luo, L.J.; Xu, B. Effects of cancer chemotherapy on the blood fibrinogen concentrations of cancer patients. J. Int. Med. Res., 2000, 28(5), 313-317.
53. Lu, D.Y.; Chen, X.L.; Huang, M.; Xu, B.; Ding, J. Relationship between blood fibrinogen concentration and pathological features of cancer patients: a 139-case clinical study. Online J. Biol. Sci., 2007, 7(1), 8-11.
54. Lu, D.Y.; Chen, X.L.; Ding, J. Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy. Med. Hypotheses, 2007, 68(1), 188-193.
55. Yogeeswaran, G.; Salk, P.L. Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science(Washington DC), 1981, 212(4502), 1514-1516.
56. Varki, A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology, 1993, 3(2), 97-130.
57. Varki, A. Diversity in the sialic acids. Glycobiology, 1992, 2(1), 25-40.
58. Hakomori, S.I. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res., 1996, 56(23), 5309-5318.
59. Kim, Y.J.; Varki, A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconjug. J., 1997, 14(5), 569-576.
60. Scanlin, T.F.; Click, M.C. Terminal glycosylation and disease: influence on cancer and cyctic fibrosis. Glycoconjug. J., 2000, 17(7-9), 617-626.
61. Nakamori, S.; Kameyama, M.; Imaoka, S.; Furukawa, H.; Ishikawa, O.; Sasaki, Y.; Kabuto, T.; Iwanaga, T.; Matsushita, Y.; Irimura, T. Increased expression of sialyl LewisX antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res., 1993, 53(15), 3632-3637.
62. Kannagi, R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconjug. J., 1997, 14(5), 577-583.